Liquidia Jumps 5.7% on EPS Beat

Liquidia Corporation's stock rose 5.7% to $58.35 after reporting Q3 2026 EPS of $1.57, beating estimates by 60.2%. Revenue was $225.3M. Analysts raised price targets, and trading volume reached 1.1M shares.

Original reporting
Published Nov 12, 2026, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Liquidia Jumps 5.7% on EPS Beat — source image
Decision brief

The 30-second read

$LQDABullishHigh
01

Why it matters

The earnings surprise is likely to attract short‑term buying and may lift related biotech stocks.

02

Market read

Primary earnings surprise with a 5.7% intraday move; relevant for traders focused on biotech earnings momentum.

03

What to watch

Potential supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 9/10Timing: today

Background

Liquidia Corp reported Q3 2026 results that exceeded expectations, prompting a notable price jump.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Q3 2026 EPS of $1.57 beat forecasts by 60.2%, sending the stock up 5.7% to $58.35.

Expected impact

upward pressure as investors price in stronger profitability.

Evidence & confidence

The surprise magnitude and volume support a short‑term rally.

Market effects

Boosts sentiment for specialty and generic pharma peers.

U.S. biotech sector may see modest gains.

Limited to pharma/biotech investors.

Counterpoint

The beat may be a one‑off; guidance remains unchanged, so caution is warranted.

Key entities

  • Liquidia Corporation

    Specialty and generic drug manufacturer.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.